

**Audited Financial Results
for the Year ended 31st March, 2007**

(Rs. in Lac)

Particulars	For 9 months		For the quarter ended		For the year ended		Consolidated year ended	
	ended 31.12.06	31.03.2007	31.03.2006	31.03.2007	31.03.2006	31.03.2007	31.03.2006	
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)	(Audited)	(Audited)	
Sales	61,122	22,857	13,747	83,979	54,797	85,060	55,352	
Less: Excise Duty	644	180	235	824	1,162	824	1,162	
Income from Operations	60,478	22,677	13,512	83,155	53,635	84,236	54,190	
Other Income	2,974	22	381	2,996	709	3,049	722	
Total Income	63,452	22,699	13,894	86,151	54,345	87,285	54,912	
(Increase) / Decrease in Stocks	(298)	1,474	(2,788)	1,176	30	1,235	130	
Consumption of Materials & bought outs	28,133	9,286	9,227	37,419	26,724	37,138	26,649	
Manufacturing Expenses	1,556	642	757	2,198	1,986	2,302	2,214	
Personnel Expenses	4,377	3,503	999	7,880	3,588	8,343	3,890	
Others	7,965	3,529	2,646	11,494	8,969	11,833	8,941	
Total Expenditure	41,733	18,434	10,841	60,167	41,297	60,851	41,823	
Interest	1,192	330	369	1,522	1,182	1,522	1,333	
Gross Profit after Interest but before Depreciation & Tax	20,527	3,935	2,684	24,462	11,866	24,912	11,756	
Depreciation	2,481	1,071	536	3,552	1,822	3,727	1,864	
Operating Profit before Tax & Extra-ordinary Items	18,046	2,864	2,148	20,910	10,044	21,185	9,891	
Extra-ordinary Items - Prior Period Expenses	-	-	13	-	23	-	23	
Profit before Tax	18,046	2,864	2,135	20,910	10,021	21,185	9,868	
Provision for taxation	4,378	261	576	4,639	2,559	4,828	2,573	
Fringe Benefits Tax	155	65	130	220	250	232	258	
Deferred Tax Liabilities/ (Assets)	1,174	196	280	1,370	1,117	1,361	1,112	
Net Profit	12,339	2,342	1,148	14,681	6,094	14,764	5,925	
Paid-up Share Capital								
Equity (Face Value Re.1/- per Share)	658	658	571	658	571	658	571	
Preference (Face Value Rs.10/- per Share)	-	-	9,043	-	9,043	-	9,043	
Reserves & Surplus				53,251	15,460	52,965	14,954	
E.P.S. (Rs.) - Basic	20.38	3.84	1.80	23.71	9.86	23.84	9.57	
E.P.S. (Rs.) - Diluted	18.64	3.52	1.58	21.73	9.64	21.85	9.36	
Aggregate of Public Shareholding								
Number of Shares	22,204,164	22,207,664	13,584,000	22,207,664	13,584,000			
Percentage of holding	33.73	33.73	23.74	33.73	23.74			

Particulars	For 9 months		For the quarter ended		For the year ended		Consolidated year ended	
	ended 31.12.06	31.03.2007	31.03.2006	31.03.2007	31.03.2006	31.03.2007	31.03.2006	
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)	(Audited)	(Audited)	
Segment Revenue								
A. Vaccines	47,506	18,881	10,830	66,387	40,669	67,441	41,224	
B. Formulations	13,228	3,774	2,754	17,002	12,965	17,002	12,965	
C. Research & Development	53	25	10	78	139	104	139	
Gross Sales/ Income from Operations	60,787	22,680	13,594	83,467	53,773	84,547	54,328	
Less : Inter Segment Revenue	-	-	-	-	-	-	-	
Net Sales/ Income from Operations	60,787	22,680	13,594	83,467	53,773	84,547	54,328	
Segment Results								
A. Vaccines	21,332	6,953	3,830	28,285	16,022	28,565	15,840	
B. Formulations	2,161	688	363	2,849	2,218	2,849	2,218	
C. Research & Development	(3,634)	(1,338)	(840)	(4,972)	(2,670)	(5,190)	(2,670)	
Total	19,859	6,303	3,353	26,162	15,570	26,224	15,388	
Less : Interest & Financial Charges	1,316	108	438	1,424	1,182	1,430	1,335	
Unallocated Overheads net of unallocated Income	497	3,331	767	3,828	4,344	3,609	4,162	
Extra-ordinary Item/ Prior Period Item	-	-	13	-	23	-	23	
Total Profit Before Tax	18,046	2,864	2,135	20,910	10,021	21,185	9,868	
Capital Employed								
A. Vaccines	24,635	29,930	19,976	29,930	19,976	29,913	19,808	
B. Formulations	21,435	15,100	14,493	15,100	14,493	15,100	14,493	
C. Research & Development	9,400	11,257	7,654	11,257	7,654	11,549	7,654	
Capital employed in Segments	55,470	56,287	42,123	56,287	42,123	56,562	41,955	
Add: Unallocable Assets Less Liabilities	(3,053)	(2,377)	(17,047)	(2,377)	(17,047)	(2,649)	(17,386)	
Total Capital employed	52,417	53,910	25,076	53,910	25,076	53,913	24,569	

Notes:

- The above financial results were reviewed by the Audit Committee of the Board and taken on record by the Board of Directors at their meetings held on 14th June, 2007.
- The Board of Directors has recommended 100% dividend (Re.1/- per Share) for the financial year 2006-07 on the Equity Share Capital of the Company.
- The Board has not recommended any further dividend for the year 2006-07 on 4.5% Preference Share Capital redeemed during the year, as the full contracted dividend, i.e. 4.5% on pro-rata time basis, has already been paid as interim dividend, as declared by the Board on 29th November, 2006.
Out of US\$100 Million Foreign Currency Convertible Bonds (FCCBs) issued during February, 2006, 8,604,904 Equity Shares were issued during the year upon conversion of FCCBs worth US\$ 55 million. Further, subsequent to March 2007, 24,688 Equity Shares were issued upon conversion of FCCBs aggregating US\$ 200,000.
Out of the net proceeds of Bonds issue, an amount of Rs.4,297.64 million has been utilised till 31st March, 2007, as under:
Capital Expenditure - Rs.1,495.70 million, Investment in Cambridge Biostability Ltd., U.K. - Rs.168.07 million, Repayment of Foreign Currency Loan - Rs.14.61 million, Used for payment of Loan and general corporate purposes - Rs.2,483.09 million and issue expenses - Rs.136.17 million.
Further, pending utilisation, an amount of Rs.173.84 million (US\$4 million) was lying in the Bank Account abroad as per FEMA Guidelines.
- Personnel expenses during the quarter include Rs.1,850 Lac towards remuneration to managerial personnel by way of commission on profits, which is subject to approval of shareholders.
- The Company has launched **Glimtotal 1, Glimtotal 2, GlizidTotal & GlibenTotal 5** Tablets (For Type 2 Diabetes) **Lower EZ** Tablet (For Diabetic Dyslipidemia), **Mycept S 180 & Mycept S 360** Tablets (Immunosuppressive agent used in Renal / Liver Transplantation) and **Dolzero** Tablet (For acute Pain), during the quarter.
- The Company's joint venture Company - Chiron Panacea Vaccines Pvt. Ltd., has registered a turnover of Rs.42.24 Crore (up by 100%) and net profit of Rs.6.35 Crore (an increase of more than 6 times) in Financial year 2006-07. The JV Company now commands market share of 35% in the paediatric combination vaccines segment in India.
- The Consolidated Financial Results have been prepared by consolidating Audited Annual Accounts for the financial year 2006-07 of its subsidiaries, viz. Radicura & Co. Ltd. and Best On Health Ltd. and Joint Venture Company, Panheber Biotech Pvt. Ltd., Audited Annual Accounts for the year ended 31st December, 2006 of Joint Venture Company, Cambridge Biostability Ltd. U.K. and Unaudited Annual Accounts for the financial year 2006-07 of Joint Venture Company, Chiron Panacea Vaccines Pvt. Ltd. Though the Annual Accounts of Chiron Panacea Vaccines have been finalised, the same are pending approval of its Board of Directors as its Board Meeting is scheduled to be held on 15th June'07.
- Status of Investors' complaints [In nos.] during the quarter, pursuant to clause 41 of listing agreement: Opening [1]; Received [1]; Disposed [2]; Closing [0].
- The previous period's figures have been regrouped/ rearranged/ reclassified wherever necessary.

New Delhi
June 14, 2007

For and on behalf of the Board
Soshil Kumar Jain
Chairman

Panacea Biotech Ltd.
Regd. Office : Ambala-Chandigarh Highway, Lallu- 140501, Punjab
Website : <http://www.panacea-biotech.com>